Patient/Clinician Resources

Understanding Cancer Immunotherapy
Patient Resource Guide

SITC leaders created the Understanding Cancer Immunotherapy Patient Guide to provide medically accurate, up-to-date information about immunotherapy that patients and their caregivers can use to understand immunotherapy, its role in cancer treatment and what to expect while undergoing this treatment.

The latest edition features disease-specific content, an expanded clinical trials section, a bladder cancer patient story and a comprehensive immunotherapy timeline.

Download your copy

It is not the goal of the guide to provide medical advice, nor will it replace the information provided by a trained medical professional.

Melanoma Immunotherapy
Patient Resource Guide

SITC leaders created the Immunotherapy for the treatment of Melanoma Patient Guide to provide current and essential information to all those involved in melanoma cancer treatment.

Download your copy

It is not the goal of the guide to provide medical advice, nor will it replace the information provided by a trained medical professional.

Melanoma Immunotherapy Guide for
Health Care Professionals

Recognizing the continued need for foundational immunotherapy education for health care professionals, SITC leaders created the Immunotherapy for the Treatment of Melanoma Health Care Professionals Guide to provide current and essential information to all those working within melanoma cancer treatment.

Download your copy

It is not the goal of the guide to provide medical advice, nor will it replace the information provided by a trained medical professional.

NSCLC Immunotherapy - Advancing Hope™

The newest in a series of videos focusing on immunotherapy for "NSCLC patients, the SITC NSCLC Immunotherapy: Advancing Hope^TM" video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some* of the FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. Through a highly informative and easy-to-understand whiteboard animated format, follow an advanced NSCLC patient who is introduced to immunotherapy and is looking to determine if it is the right treatment option for him.

This video was produced in collaboration with several other leading organizations across the continuum of cancer care, including Association of Oncology Social Work, Association of Community Cancer Centers, Bonnie J. Addario Lung Cancer Foundation, Cancer Support Community, Lung Cancer Alliance, and LUNGevity.

View the video now.

*This video was produced prior to the October 2016 FDA approvals of 1) TECENTRIQ^® (atezolizumab, Genetech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA^® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update this video series as additional immunotherapy treatments become available.

NSCLC Immunotherapy - A New Hope™

Created by the Society for Immunotherapy of Cancer (SITC), “Non-Small Cell Lung Cancer Immunotherapy: A New Hope,” follows a patient’s journey from her diagnosis of NSCLC through the course of cancer immunotherapy treatment via a clinical trial. Through an engaging, white board animated format, this video provides patients with easy-to-understand and unbiased information on how cancer immunotherapy works, as well as informative discussion regarding cancer immunotherapy clinical trials for patients with NSCLC.

This video was produced in collaboration with several other leading organizations across the continuum of cancer care, including Association of Community Cancer Centers, Bonnie J. Addario Lung Cancer Foundation, Cancer Support Community, Lung Cancer Alliance, and LUNGevity.

View the video now.

This video was produced prior to the 2015 US FDA approvals of  Opdivo^® (nivolumab) for the treatment of squamous and non-squamous non-small cell lung cancer and Keytruda^® (pembrolizumab) for the treatment of non-small cell lung cancer in patients whose tumors express PD-L1. More educational resources will be developed in this area as advancements in the field continue.